title: Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer.
abstract: The major aim of neoadjuvant systemic therapy is to improve prognosis by individualizing treatment. The proven benefits of neoadjuvant systemic therapy include reducing tumor burden, higher breast-conserving surgery, and the possibility of in vivo monitoring of response to treatment. Other goals of neoadjuvant treatment are the detection of new prognostic and predictive biomarkers and the investigation of new drugs and imaging modalities. Although many prospective trials have answered important questions regarding neoadjuvant systemic therapy, several topics remain controversial.
authors.affiliation: Department of Obstetrics and Gynecology and Breast Unit, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60 590, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
authors.forename: Manfred
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Karn
authors.forename: Eugen
authors.initials: E
authors.lastname: Ruckhäberle
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018579:Patient Selection; D011379:Prognosis; D018714:Radiotherapy, Adjuvant
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor